Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Mark Smith Biography and Net Worth

Director of Jazz Pharmaceuticals

Mark D. Smith, M.D. has an impressive background that marries the worlds of active medical practice and business development. A practicing physician and professor, Dr. Smith also has experience working for a variety of health focused companies both public and private. Additionally, Dr. Smith allocates part of his time for nonprofit organizations and a health policy foundation. Dr. Smith believes that increasing the role of value-based payment is the most exciting current development in medicine, as the system requires an innovative overhaul.

Dr. Smith has served as a member of our board of directors since December 2020. Dr. Smith is a practicing physician and professor of clinical medicine at the University of California at San Francisco, where he has served since 1994. He also serves as a non-executive director on the boards of directors of two publicly-held companies, Teladoc Health, Inc., a telemedicine and virtual healthcare company which recently merged with Livongo, and Phreesia, Inc., a healthcare software company. Dr. Smith also serves on the boards of directors of The Commonwealth Fund, a private health policy foundation, and the Institute for Health Care Improvement, an independent nonprofit organization pursuing quality improvement in health care around the world. From 1996 to 2013, Dr. Smith was the founding President and Chief Executive Officer of the California HealthCare Foundation, an independent nonprofit philanthropy organization. From 1991 to 1996, he served as Executive Vice President at the Henry J. Kaiser Family Foundation. Dr. Smith received a B.A. from Harvard College, an M.D. from the University of North Carolina at Chapel Hill and an M.B.A. from The Wharton School at the University of Pennsylvania.

What is Mark Douglas Smith's net worth?: The estimated net worth of Mark Douglas Smith is at least $750,034.32 as of December 4th, 2023. Dr. Smith owns 6,888 shares of Jazz Pharmaceuticals stock worth more than $750,034 as of April 26th. This net worth evaluation does not reflect any other investments that Dr. Smith may own. Learn More about Mark Douglas Smith's net worth.
How do I contact Mark Douglas Smith?: The corporate mailing address for Dr. Smith and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Mark Douglas Smith's contact information.
Has Mark Douglas Smith been buying or selling shares of Jazz Pharmaceuticals?: Mark Douglas Smith has not been actively trading shares of Jazz Pharmaceuticals during the last quarter. Most recently, Mark Douglas Smith sold 417 shares of the business's stock in a transaction on Monday, December 4th. The shares were sold at an average price of $119.27, for a transaction totalling $49,735.59. Following the completion of the sale, the director now directly owns 6,888 shares of the company's stock, valued at $821,531.76. Learn More on Mark Douglas Smith's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Robert Iannone (EVP), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 10 times. They sold a total of 13,870 shares worth more than $1,827,470.63. The most recent insider tranaction occured on March, 6th when CAO Patricia Carr sold 1,936 shares worth more than $231,623.04. Insiders at Jazz Pharmaceuticals own 4.4% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 3/6/2024.

Mark Douglas Smith Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/4/2023	Sell	417	$119.27	$49,735.59	6,888
12/2/2021	Sell	417	$121.30	$50,582.10

Mark Douglas Smith Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $108.89

$106.73

$109.16

50 Day Range

MA: $118.60

$107.10

$132.77

2 Week Range

Now: $108.89

$106.61

$146.70

Volume

104,483 shs

Average Volume

599,671 shs

Market Capitalization

$6.86 billion

P/E Ratio

17.79

Dividend Yield

N/A

Beta

0.59

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

From Priority Gold | Ad